ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $44.00 at HC Wainwright

ArriVent BioPharma (NASDAQ:AVBP) had its target price boosted by HC Wainwright from $42.00 to $44.00 in a research report released on Friday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Several other research firms also recently weighed in on AVBP. Citigroup dropped their target price on shares of ArriVent BioPharma from $33.00 to $31.00 and set a “buy” rating on the stock in a research report on Tuesday, November 11th. Cantor Fitzgerald assumed coverage on shares of ArriVent BioPharma in a research note on Monday, December 22nd. They set an “overweight” rating for the company. Zacks Research raised shares of ArriVent BioPharma from a “strong sell” rating to a “hold” rating in a report on Friday, December 5th. BTIG Research initiated coverage on ArriVent BioPharma in a research report on Wednesday, December 10th. They issued a “buy” rating and a $45.00 target price on the stock. Finally, Truist Financial assumed coverage on ArriVent BioPharma in a research note on Tuesday, November 25th. They issued a “buy” rating and a $43.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $41.11.

ArriVent BioPharma Stock Performance

NASDAQ:AVBP traded down $1.82 during mid-day trading on Friday, hitting $23.43. 1,788,123 shares of the company’s stock traded hands, compared to its average volume of 393,931. The company has a fifty day moving average of $22.20 and a 200 day moving average of $20.92. ArriVent BioPharma has a twelve month low of $15.47 and a twelve month high of $27.22. The company has a market capitalization of $967.19 million, a P/E ratio of -5.31 and a beta of 0.99.

ArriVent BioPharma (NASDAQ:AVBP) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($0.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.09. On average, research analysts expect that ArriVent BioPharma will post -2.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AVBP. Virtu Financial LLC purchased a new stake in ArriVent BioPharma in the fourth quarter valued at $227,000. Invesco Ltd. grew its position in ArriVent BioPharma by 12.5% during the 4th quarter. Invesco Ltd. now owns 16,892 shares of the company’s stock worth $340,000 after purchasing an additional 1,876 shares during the period. XTX Topco Ltd purchased a new position in shares of ArriVent BioPharma during the 4th quarter valued at about $528,000. Virtus Investment Advisers LLC lifted its holdings in shares of ArriVent BioPharma by 126.2% in the 4th quarter. Virtus Investment Advisers LLC now owns 10,894 shares of the company’s stock valued at $219,000 after buying an additional 6,078 shares during the period. Finally, Wellington Management Group LLP lifted its holdings in shares of ArriVent BioPharma by 0.7% in the 4th quarter. Wellington Management Group LLP now owns 82,278 shares of the company’s stock valued at $1,655,000 after buying an additional 532 shares during the period. 9.48% of the stock is currently owned by institutional investors and hedge funds.

Key ArriVent BioPharma News

Here are the key news stories impacting ArriVent BioPharma this week:

• Positive Sentiment: Oppenheimer reaffirmed an “outperform” rating and raised its price target to $50 (from $44), a large upside vs. the current price. Oppenheimer boosts PT to $50
• Positive Sentiment: Citigroup raised its price target from $31 to $33 and kept a “buy” rating, signaling more analyst conviction. Citigroup raises PT to $33
• Positive Sentiment: HC Wainwright raised its target from $42 to $44 and maintained a “buy” rating—another analyst upgrade supporting upside. HC Wainwright raises PT to $44
• Positive Sentiment: Unusually large options activity: traders bought about 1,832 call contracts (?321% above typical call volume), indicative of short-term bullish positioning.
• Positive Sentiment: Quarterly EPS beat: AVBP reported loss-per-share of ($0.78) vs. consensus ($0.87), a small beat that reduces near-term execution risk. Quarterly results press release
• Neutral Sentiment: Company released full-year 2025 financial results and highlighted progress; no headline surprises were reported in the summary notice. Full-year 2025 results
• Neutral Sentiment: Consensus brokerage coverage remains constructive (“Moderate Buy”), reflecting overall analyst support but not an immediate catalyst. Consensus recommendation coverage
• Neutral Sentiment: Reported short-interest entries show inconsistent/zero values (data artifact), so there’s no clear evidence of rising short pressure based on the published figures.
• Negative Sentiment: Despite the bullish signals above, AVBP is trading down on heavy volume — likely profit-taking, option-driven hedging flows, or broader market weakness outweighing analyst upgrades in the near term. Investors should watch intraday volume, near-term option activity, and any sector-wide moves for further direction.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.